General
Preferred name
JNJ-7706621
Synonyms
aurora kinase/Cdk inhibitor ()
JNJ7706621 ()
Aurora kinase/CDK inhibitor, cmpd 3b ()
JNJ 7706621 ()
P&D ID
PD011042
CAS
443797-96-4
Tags
available
drug candidate
obsolete probe
Drug indication
Discovery agent
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Some bioactivity data may be associated with the acetonitrile compound (PubChem CID 16760303).
DESCRIPTION
JNJ-7706621 was originally identified as a pan-CDK and Aurora A/B kinase inhibitor . JNJ-7706621 binding to the pseudo (JH2) kinase domain of Janus kinase 2 has been reported more recently . This mechanism of JAK inhibition is viewed as offering a potentially novel pharmacological modality as an alternative to targeting the active kinase (JH1) domain and its ATP binding pocket.
(GtoPdb)
DESCRIPTION
JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits CDK1 and CDK2, with IC50s of 9 nM, 3 nM, 11 nM, and 15 nM for CDK1, CDK2, aurora-A and aurora-B, respectively[1][2][3].
PRICE
154
DESCRIPTION
JNJ-7706621 is a novel cell cycle inhibitor that showed potent inhibition of several cyclin-dependent kinases (CDK) and Aurora kinases and selectively blocked proliferation of tumor cells of various origins but was about 10-fold less effective at inhibiting normal human cell growth in vitro. In human cancer cells, treatment with JNJ-7706621 inhibited cell growth independent of p53, retinoblastoma, or P-glycoprotein status; activated apoptosis; and reduced colony formation. At low concentrations, JNJ-7706621 slowed the growth of cells and at higher concentrations induced cytotoxicity.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
JNJ-7706621 is a potent aurora kinase inhibitor that also inhibits CDK1 and CDK2.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
6
Organisms
0
Compound Sets
14
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
CDK inhibitor database (CDKiDB)
Drug Repurposing Hub
DrugMAP
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
Obsolete Compounds
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
26
Molecular Weight
394.07
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
3
Rotatable Bonds
4
Ring Count
3
Aromatic Ring Count
3
cLogP
1.22
TPSA
145.99
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
6.0
QED
0.6
Structural alerts
1
historic compounds (Chemical Probes.org)
Obsolete
Related compounds
Custom attributes
(extracted from source data)
Target
Apoptosis
Aurora A
Aurora B
Aurora Kinase
CDK
CDK1/CyclinB
CDK2/CyclinA
CDK2/CyclinE
AURKA, AURKB, CDK1, CDK2
Aurora Kinase,CDK
Member status
member
MOA
Antimitotic Drugs
Apoptosis Inducers
Aurora Kinase Inhibitors
CDK1/Cyclin B Inhibitors
CDK2/Cyclin A Inhibitors
Inhibitors of Signal Transduction Pathways
CDK inhibitor
Pathway
Cell Cycle/Checkpoint
Chromatin/Epigenetic
Cell Cycle/DNA Damage
Epigenetics
Source data
